专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006084474A3 A STABLE PHARMACEUTICAL COMPOSITION COMPRISING A FIXED DOSE COMBINATION OF FENOFIBRATE AND AN HMG-COA REDUCTASE INHIBITOR 审中-公开
标题翻译：包含FENOFIBRATE和HMG-COA还原酶抑制剂的固定剂量组合的稳定的药物组合物
公开(公告)号：WO2006084474A3
公开(公告)日：2006-11-02
申请号：PCT/DK2006050004
申请日：2006-02-10
申请人： LIFECYCLE PHARMA AS , HOLM PER , NORLING TOMAS
发明人： HOLM PER , NORLING TOMAS
IPC分类号： A61K31/216 , A61K9/16 , A61K9/24 , A61K9/26 , A61K31/366 , A61K31/40
CPC分类号： A61K45/06 , A61K9/209 , A61K31/216 , A61K31/366 , A61K31/40 , A61K2300/00
摘要： A pharmaceutical composition for oral administration comprising a fixed dose combination of a first solid pharmaceutical composition containing fenofibrate as the active substance and second solid pharmaceutical composition containing an HMG-CoA reductase inhibitor such as a statin as the active substance, wherein the first and the second pharmaceutical compositions are present in separate entities in a single solid dosage form. For example a multilayer tablet, a two-layer tablet, or capsules or sachets containing the active ingredients in separate granulates or beads, either granulate or bead optionally being coated with a protective coating or an entero-coating.
摘要翻译：一种口服给药用药物组合物，其含有含有非诺贝特作为活性物质的第一固体药物组合物和含有HMG-CoA还原酶抑制剂如他汀的第二固体药物组合物作为活性物质的固定剂量组合，其中第一和第二药物组合物以单独的实体存在于单一固体剂型中。例如，多层片剂，双层片剂或含有分开的颗粒或珠粒中的活性成分的胶囊或囊剂，颗粒或珠粒任选地涂覆有保护性涂层或肠道包衣。

2. 发明申请

WO2006037345A1 PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRATE AND SIMVASTATIN 审中-公开
标题翻译：包含芬太尼和辛伐他汀的药物组合物
公开(公告)号：WO2006037345A1
公开(公告)日：2006-04-13
申请号：PCT/DK2005/050002
申请日：2005-10-03
申请人： LIFECYCLE PHARMA A/S , HOLM, Per , NORLING, Tomas
发明人： HOLM, Per , NORLING, Tomas
IPC分类号： A61K9/14 , A61K9/20 , A61K31/216 , A61K31/366 , A61P3/06
CPC分类号： A61K9/209 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2031 , A61K9/2077 , A61K9/5084 , A61K31/216 , A61K31/366 , A61K2300/00
摘要： Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor simvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 800 and about 29,300. The solid compositions are manufactured without any need of addition of water or aqueous medium. Simvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.
摘要翻译：包含非诺贝特和HMG CoA还原酶抑制剂辛伐他汀或其药物活性盐的组合的药物组合物，其在口服给药后提供约800的相对AUC 0-24值（AUCfibric acid / AUCatorvastatin）约29,300。制造固体组合物，而不需要加入水或水性介质。辛伐他汀任选地作为控制释放或延迟释放制剂提供，导致在减少的剂量下维持LDL降低作用，并且在具有增加的生物利用度和降低的食物效应的制剂中提供非诺贝特。

3. 发明申请

WO2005034908A2 A SOLID DOSAGE FORM COMPRISING A FIBRATE AND A STATIN 审中-公开
标题翻译：包含纤维蛋白和肌肽的固体剂型
公开(公告)号：WO2005034908A2
公开(公告)日：2005-04-21
申请号：PCT/DK2004/000668
申请日：2004-10-01
申请人： LIFECYCLE PHARMA A/S , HOLM, Per , NORLING, Tomas
发明人： HOLM, Per , NORLING, Tomas
IPC分类号： A61K9/00
CPC分类号： A61K31/366 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/2018 , A61K9/2077 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K31/505 , A61K45/06 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors), which compositions are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e. the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration.
摘要翻译：本发明涉及颗粒形式或固体剂型的药物组合物，其包含贝特盐，特别是非诺贝特和他汀类（也称为HMG CoA还原酶抑制剂）的组合，所述组合物是不需要添加水或水性介质而制造，并且其中至少80％的活性物质（即贝特类和他汀类）以溶解形式存在于组合物中，以确保两种活性成分在口服后适当的生物利用度施用

4. 发明申请

WO2006084475A2 A TABLET COMPRISING A FIBRATE 审中-公开
标题翻译：含有纤维素的片剂
公开(公告)号：WO2006084475A2
公开(公告)日：2006-08-17
申请号：PCT/DK2006050014
申请日：2006-04-12
申请人： LIFECYCLE PHARMA AS , HOLM PER , NORLING TOMAS
发明人： HOLM PER , NORLING TOMAS
IPC分类号： A61K9/20
CPC分类号： A61K9/2077 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2081 , A61K9/5078
摘要： Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state.
摘要翻译：颗粒形式的稳定片剂和药物组合物，其包含贝特类，例如非诺贝特，溶解或分散在具有改善的生物利用度的非水性载体中，由此消除食物效应，使得片剂或组合物可以施用于患者，而不管其是否在进食或禁食状态。

5. 发明申请

WO2005034920A1 A SOLID DOSAGE FORM COMPRISING A FIBRATE 审中-公开
标题翻译：一种包含纤维素的固体剂型
公开(公告)号：WO2005034920A1
公开(公告)日：2005-04-21
申请号：PCT/DK2004/000667
申请日：2004-10-01
申请人： LifeCycle Pharma A/S , HOLM, Per , NORLING, Tomas
发明人： HOLM, Per , NORLING, Tomas
IPC分类号： A61K9/20
CPC分类号： A61K9/20 , A61K9/2013 , A61K9/2018 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
摘要翻译：本发明提供稳定的固体剂型和药物组合物，其包含溶解在非水载体中的贝特类，例如非诺贝特，以确保相对于已知的贝特类制剂口服给药时活性成分的生物利用度得到改善。

6. 发明申请

WO2010024744A1 METHOD FOR DETECTING HARDWARE FAULTS BY DETERMINING A RATIO OF RELEASED CONNECTIONS 审中-公开
标题翻译：通过确定释放连接比例来检测硬件故障的方法
公开(公告)号：WO2010024744A1
公开(公告)日：2010-03-04
申请号：PCT/SE2008/050973
申请日：2008-08-28
申请人： TELEFONAKTIEBOLAGET L M ERICSSON (PUBL) , ZEE, Oscar , NORLING, Tomas
发明人： ZEE, Oscar , NORLING, Tomas
IPC分类号： H04L12/24 , H04W24/08
CPC分类号： H04W24/06 , H04L41/5035
摘要： The present invention provides a method of detecting a faulty network element in a network, the network comprising at least a plurality of first network elements having a first network element type, and at least a plurality of second network elements having a second network element type. The method comprises the steps of: a) selecting one of the plurality of first network elements and one of the plurality of second network elements; b) attempting to set up a connection between said selected first network element and said selected second network element; c) repeating steps a) and b) for further selected first and second network elements; d) for each of the plurality of first network elements and for each of the plurality of second network elements, counting a number of connections that are released as the result of a fault; and e) for a particular one of the first or second network elements, on the basis of said number of connections that are released in said particular network element as a result of a fault, determining whether said particular network element is faulty.
摘要翻译：本发明提供一种检测网络中故障网元的方法，所述网络包括至少多个具有第一网元类型的第一网元和至少具有第二网元类型的第二网元。该方法包括以下步骤：a）选择多个第一网元中的一个和多个第二网元中的一个; b）尝试在所述选择的第一网络元件和所选择的第二网络元件之间建立连接; c）对进一步选择的第一和第二网络元件重复步骤a）和b）; d）对于所述多个第一网络元件中的每一个以及对于所述多个第二网络元件中的每一个，对由于故障而被释放的连接数进行计数; 以及e）对于所述第一或第二网络元件中的特定的一个，基于作为故障的结果在所述特定网络元件中释放的所述连接数量，确定所述特定网络元件是否有故障。

7. 发明申请

WO2006037344A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FENOFIBRATE AND ATORVASTATIN 审中-公开
标题翻译：包含芬太尼和ATORVASTATIN的药物组合物
公开(公告)号：WO2006037344A1
公开(公告)日：2006-04-13
申请号：PCT/DK2005/050001
申请日：2005-10-03
申请人： LIFECYCLE PHARMA A/S , HOLM, Per , NORLING, Tomas
发明人： HOLM, Per , NORLING, Tomas
IPC分类号： A61K9/14 , A61K9/20 , A61K31/216 , A61K31/40 , A61P3/06
CPC分类号： A61K9/1617 , A61K9/1611 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K9/2077 , A61K9/209 , A61K9/4808 , A61K9/5084 , A61K31/216 , A61K31/40 , A61K2300/00
摘要： Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compositions are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.
摘要翻译：包含非诺贝特和HMG CoA还原酶抑制剂阿托伐他汀或其药物活性盐的组合的药物组合物，其在口服给药时提供约250μg的相对AUC 0-24值（AUCfibric acid / AUCatorvastatin）约10,000。制造固体组合物，而不需要加入水或水性介质。任选地提供阿托伐他汀作为控制释放或延迟释放制剂，导致在减少的剂量下维持的LDL降低作用，并且在具有增加的生物利用度和降低的食物效应的制剂中提供非诺贝特。

8. 发明申请

WO2005053660A3 PHARMACEUTICAL COMPOSITIONS COMPRISING DANAZOL 审中-公开
标题翻译：包含DANAZOL的药物组合物
公开(公告)号：WO2005053660A3
公开(公告)日：2005-10-20
申请号：PCT/DK2004000844
申请日：2004-12-03
申请人： LIFECYCLE PHARMA AS , HOLM PER , NORLING TOMAS
发明人： HOLM PER , NORLING TOMAS
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/28 , A61K9/50 , A61K31/00 , A61K31/58 , A61K47/02
CPC分类号： A61K9/1611 , A61K9/146 , A61K9/1623 , A61K9/1635 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K9/5026 , A61K9/5042 , A61K31/00 , A61K31/58 , A61K47/02
摘要： A controlled release pharmaceutical comprising danazol has the property of slow release of danazol over an extended period of time and markedly increased bioavailability compared to commercially available danazol-containing products. The pharmaceutical composition comprises danazol dissolved in a solid vehicle or carrier and is especially suitable for oral solid dosage forms. The composition significantly reduces food effect and may reduce side effects.
摘要翻译：包含达那唑的控释药物具有延长的时间段缓释丹那唑的性质，与市售的含达那唑的产品相比显着提高了生物利用度。药物组合物包含溶于固体载体或载体中的达那唑，特别适用于口服固体剂型。该组合物显着降低食物的作用并可能减少副作用。

9. 发明申请

WO2005034908A3 A SOLID DOSAGE FORM COMPRISING A FIBRATE AND A STATIN 审中-公开
标题翻译：一种包含纤维素和固体的固体剂型
公开(公告)号：WO2005034908A3
公开(公告)日：2005-08-11
申请号：PCT/DK2004000668
申请日：2004-10-01
申请人： LIFECYCLE PHARMA AS , HOLM PER , NORLING TOMAS
发明人： HOLM PER , NORLING TOMAS
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/505 , A61K45/06 , A61K9/48
CPC分类号： A61K31/366 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2013 , A61K9/2018 , A61K9/2077 , A61K31/192 , A61K31/195 , A61K31/216 , A61K31/22 , A61K31/40 , A61K31/505 , A61K45/06 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors), which compositions are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e. the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration.
摘要翻译：本发明涉及颗粒形式或固体剂型的药物组合物，其包含贝特类，特别是非诺贝特和他汀类（也称为HMG CoA还原酶抑制剂）的组合，该组合物在不需要添加水的情况下制造或水性介质，并且其中至少80％的活性物质（即贝特类和他汀类）以溶解形式存在于组合物中，以确保口服给药时两种活性成分的合适的生物利用度。

10. 发明申请

WO2005032525A1 A METHOD FOR PREPARING MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：一种制备改性释放药物组合物的方法
公开(公告)号：WO2005032525A1
公开(公告)日：2005-04-14
申请号：PCT/DK2004/000669
申请日：2004-10-04
申请人： LIFECYCLE PHARMA A/S , HOLM, Per , NORLING, Tomas
发明人： HOLM, Per , NORLING, Tomas
IPC分类号： A61K9/48
CPC分类号： A61K9/2031 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K9/2866 , A61K9/5026 , A61K9/5047
摘要： A method for the preparation of a pharmaceutical particulate composition for modified release of one or more therapeutically, prophylactically and/or diagnostically active substances, the method involving spraying of a composition comprising an oily material on a solid composition in order to subject the solid composition to a controlled agglomeration process, whereby individual particles are aggregated into agglomerates in a controlled manner and a relatively small particle size and particle size distribution is obtained, the particulate composition comprising a sufficient amount of at least one release-rate modifying substance to provide a modified release of the active substance sufficient to provide duration of therapeutic, prophylactic and/or diagnostic effect of at least about 2 hours when the composition is exposed to an aqueous environment.
摘要翻译：一种用于制备用于一种或多种治疗，预防和/或诊断活性物质的改性释放的药物颗粒组合物的方法，所述方法包括将固体组合物上含有油性物质的组合物喷雾以使固体组合物受控的团聚过程，其中单独的颗粒以受控的方式聚集成团聚体，并且获得相对较小的粒度和粒度分布，所述颗粒组合物包含足够量的至少一种释放速率改性物质以提供改性释放的活性物质足以在组合物暴露于水性环境中时提供至少约2小时的治疗，预防和/或诊断作用的持续时间。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式